Description
Carfilzomib is a proteasome inhibitor indicated for the treatment of:
- Adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with:
- Lenalidomide and dexamethasone
- Dexamethasone
- Daratumumab and dexamethasone
- Daratumumab and hyaluronidase-fihj and dexamethasone
- As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
Dosage and Side Effects
How you take Carfilzomib depends on your treatment plan. Your doctor will provide specific instructions based on your condition. Drink plenty of fluids before and after taking Carfilzomib, as needed.
- If you’re using Carfilzomib with Dexamethasone (Kd), Carfilzomib with Daratumumab and Dexamethasone (DKd), or Carfilzomib with Daratumumab, hyaluronidase-fihj, and Dexamethasone (DKd), you’ll take 20/70 mg/m² once a week, and the treatment will last for about 30 minutes.
- If you’re using Kd, DKd, or taking Carfilzomib alone, you’ll take 20/56 mg/m² twice a week, and each treatment session will be around 30 minutes.
- If you’re taking Carfilzomib with Lenalidomide and Dexamethasone (KRd) or Carfilzomib alone, you’ll take 20/27 mg/m² twice a week, and each session will last about 10 minutes.
The common side effects of Carfilzomib are anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral.
Warning and Precautions
Carfilzomib is associated with several warnings and precautions, including:
- Cardiac Toxicities: Monitor for signs and symptoms of cardiac failure or ischemia. Withhold Carfilzomib and evaluate promptly.
- Acute Renal Failure: Monitor serum creatinine regularly.
- Tumor Lysis Syndrome (TLS): Administer pre-treatment hydration and monitor for TLS, including uric acid levels, and treat promptly.
- Pulmonary Toxicity: Withhold Carfilzomib and evaluate promptly in case of pulmonary issues.
- Hypertension: Monitor blood pressure regularly and interrupt treatment with if Carfilzomib hypertension cannot be controlled.
- Venous Thrombosis: Thromboprophylaxis is recommended.
- Infusion-related Reactions: Premedicate with dexamethasone.
- Hemorrhage: Monitor for signs and symptoms of blood loss.
- Thrombocytopenia: Monitor platelet counts and adjust dosing as needed.
- Hepatic Toxicity and Hepatic Failure: Monitor liver enzymes regularly and withhold Carfilzomib if suspected.
- Thrombotic Microangiopathy: Monitor for signs and symptoms and discontinue Carfilzomib if suspected.
- Posterior Reversible Encephalopathy Syndrome (PRES): Consider neuro-radiological imaging and discontinue Carfilzomib if suspected.
- Progressive Multifocal Leukoencephalopathy (PML): Consider PML in patients with new or worsening neurologic manifestations and discontinue Carfilzomib if PML is suspected.
- Increased Fatal and Serious Toxicities in Combination with Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Patients.
- Embryo-Fetal Toxicity: Carfilzomib can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential.
FAQ's
Is carfilzomib FDA approved?
On November 30, 2021, the Food and Drug Administration approved daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.)
What is the warning for carfilzomib?
Other warnings and precautions of Carfilzomib include cardiac toxicities, acute renal failure, tumor lysis syndrome, pulmonary toxicity, pulmonary hypertension, dyspnea, hypertension, venous thrombosis, infusion reactions, thrombocytopenia, hepatic toxicity and hepatic failure, thrombotic microangiopathy, posterior .
Is carfilzomib a chemo drug?
Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
What is the action of carfilzomib?
Mechanism. Carfilzomib covalently irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme that degrades unwanted cellular proteins. Carfilzomib displays minimal interactions with non-proteasomal targets, thereby improving safety profiles over bortezomib.
How long is carfilzomib treatment?
When do you have carfilzomib and dexamethasone? of treatment. Each cycle is 28 days (4 weeks). You have both drugs two days in a row every week for 3 weeks, followed by a week with two days of dexamethasone on its own.
